Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1999-02-23
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 14, 514 16, 530327, 530328, 530326, A61K 3800, C09K 500
Patent
active
058744096
ABSTRACT:
aPL analogs that (a) bind specifically to B cells to which the aPL epitope binds and (b) lack T cell epitope(s), methods preparing and identifying said analogs and methods of treatment using said analogs are disclosed.
REFERENCES:
patent: 5162515 (1992-11-01), Conrad et al.
patent: 5268454 (1993-12-01), Barstad et al.
patent: 5276013 (1994-01-01), Conrad et al.
patent: 5344758 (1994-09-01), Krilis et al.
patent: 5472883 (1995-12-01), Matsuura et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5506110 (1996-04-01), Matsuura et al.
patent: 5552391 (1996-09-01), Coutts et al.
Haas et al., "Rapid sequencing of viral DNA from filamentous bacteriophage" (1993) BioTechniques 15:422-423, 426, 428-429.
Sanger et al., "DNA sequencing with chain-terminating inhibitors" (1977) Proc. Natl. Acad. Sci. USA 74:5463-5467.
Harris, "Antiphospholipid antibodies" (1990) Brit. J. Haemotol. 74:1-9.
Aichele et al., "Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model" (1994) Proc. Natl. Acad. Sci. USA 91:444-448.
Elliott, "Anergy and suppression in B-cell responses" (1992) Scand J. Immunol. 36:761-767.
McConathy et al., "Isolation and characterization of other apolipoproteins" Meth. Enzymol. (1986) 128:296-310.
Nonaka et al., "Molecular cloning of mouse .beta..sub.2 -glycoprotein I and mapping of the gene to chromosome 11" Genomics (1992) 13:1082-1087.
Kato et al., "Amino acid sequence and location of the disulfide bonds in bovine .beta.2 glycoprotein I: The presence of five sushi domains" Biochem. (1991) 30:11687-11694.
Steinkasserer et al., "Complete nucleotide and deduced amino acid sequence of human .beta..sub.2 -glycoprotein I" Biochem. J. (1991) 277:387-391.
Petri et al., "Diagnosis of antiphospholipid antibodies" Rheumatic Disease Clinics of North America, (1994) 20(2):443-469.
McCarty-Farid "Antiphospholipid antibodies in systemic lupus erythematosus and Sjorgen's syndrome" Current Opinion in Rheumatology (1993) 5:596-603.
Valesini et al., "A new player in the antiphospholipid syndrome: the .beta..sub.2 glycoprotein I cofactor" Autoimmunity (1992) 14:105-110.
Wang et al., "Epitope specificity of monoclonal anti-.beta..sub.2 -glycoprotein I antibodies derived from patients with the antiphospholipid syndrome" J. Immunol. (1995) 155:1629-1636.
Gharavi et al., "Induction of antiphospholipid antibodies by immunization with a 15-amino acid peptide spanning the phospholipid binding site of .beta..sub.2 glycoprotein I" J. Invest. Med. (1996) 44:69A.
Harris et al., eds., Phospholipid-Binding Antibodies, (1991) CRC Press, Boca Raton, FL. The title page and table of contents are enclosed herewith.
McNeil et al., "Immunology and clinical importance of antiphospholipid antibodies" Adv. Immunol. (1991) 49:193-280.
Bakimer et al., "Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3)" J. Clin. Invest. (1992) 89:1558-1563.
Blank et al., "Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies" Proc. Natl. Acad. Sci. USA (1991) 88:3069-3073.
McNeil et al., Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: .beta..sub.2 -glycoprotein I (apoliprotein H) Proc. Natl. Acad. Sci. (1990) 87:4120-4124.
Galli et al., "Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor" Lancet (1990): pp. 1544-1547.
Wagenknecht et al., "Changes in .beta..sub.2 -glycoprotein I antigenicity induced by phospholipid binding" Thromb. Haemostas. (1993) 69:361-365.
Jones et al., "Antigenic specificity of anticardiolipin antibodies appears to depend on conformation of .beta..sub.2 -glycoprotein I" (Sep. 9-12, 1992) Proc. 5th Intl. Symp. Antiphospholipid Antibodies, Hyatt Regency San Antonio, Texas, (Abstract S5) (4 pages total).
Hunt et al., "The fifth domain of .beta..sub.2 -glycoprotein I contains a phospholipid binding site (cys281-cys288) and a region recognized by anticardiolipin antibodies" J. Immunol. (1994) 152:653-659.
Lauer et al., "Amino acid sequence of the region of .beta..sub.2 -glycoprotein 1 (gp1) which mediates binding of autoantibodies to the cardiolipin-gp1 complex in humans" Immunol. (1993) 80:22-28.
Hasselaar et al., "Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets" Thromb. Haemostas. (1990) 63:169-173.
Vermylen et al., "Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?" J. Clin. Lab. Med. (1992) 120:10-12.
Arvieux et al., "Platelet activating properties of murine monoclonal antibodies to .beta..sub.2 -glycoprotein I" Thromb. Haemostas. (1993) 70:336-341.
Scott., J.K., "Identifying lead peptides from epitope libraries" Biological Approaches to Rational Drug Design GN (CRC Press, Weiner, D. B. and W.V. Williams, eds., Boca, Raton, FL., 1994), Chapter 1, pp. 1-28. The title page and table of contents are enclosed herewith.
Moos et al., "Recent advances in the generation of molecular diversity" Ann. Reports Med. Chem. (1993) 28:315-324.
Scott et al., "Searching for peptide ligands with an epitope library" Science (1990) 249:386-390.
Cesareni, "Peptide display on filamentous phage capsids" FEBS Lett. (1992) 307:66-70.
Luzzago et al., "Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides" Gene (1993) 128:51-57.
Balass et al., "Identification of a hexapeptide that mimics a conformation-dependent binding site of acetycholine receptor by use of a phage-epitope library" Proc. Natl. Acad. Sci. USA (1993) 90:10638-10642.
Powell, "Peptide stability in drug development: In vitro peptide degradation in plasma and serum" Ann. Reports Med. Chem. (1993) 28:285-294.
Reber et al., "Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies" (1995) Thrombosis and Haemostat. 73:444-452.
Scott et al., "Searching for peptide ligands with an epitope library" (1990) Science 249:386-390.
Barbas III et al., "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site" (1991) Proc. Natl. Acad. Sci. USA 88:7978-7982.
Posnett et al., "A novel method for producing anti-peptide antibodies" (1988) J. Biol. Chem. 263:1719-1725.
Steinkasserer et al., "Activity, disulphide mapping and structural modelling of the fifth domain of human .beta..sub.2 -glycoprotein I" FEBS Lett. (1992) 313:193-197.
Holmes et al., "A rapid boiling method for the preparation of bacterial plasmids" (1981) Anal. Biochem. 144:193-197.
Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed., (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. The title page and table of contents are included herewith.
Cwirla et al., "Peptides on phage: A vast library of peptides for identifying ligands" Proc. Natl. Acad. Sci. USA (1990) 87:6378-6382.
Dower et al., "High efficiency transformation of E. coli by high voltage electroporation" (1988) Nucleic Acid Res. 16:6127-6145.
Smith et al., "Libraries of peptides and proteins displayed on filamentous phage" (1993) Meth. Enzymol. 217:228-257.
Brighton et al. (Sep. 1994) Baillieres Clin. Haematol. vol. 7(3): 165-74.
Kandiah et al. (1995) Lupus vol. 4 Supp. 1 S7-S11.
Marquis David Matthew
Victoria Edward Jess
Eisenschenk Frank C.
La Jolla Pharmaceutical Company
Nolan Patrick J.
LandOfFree
APL immunoreactive peptides, conjugates thereof and methods of t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with APL immunoreactive peptides, conjugates thereof and methods of t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and APL immunoreactive peptides, conjugates thereof and methods of t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-306974